NewCo licensing models are tipping deals in favour of China’s biotechs
As pharma companies continue to license candidates developed in China, experts say a particular licensing model is allowing the country's…
Analysis
The dangerous second life of medical waste
The Baltics: a region punching above its weight on the global life sciences stage
Magazine: China’s CGT edge
What does the EU Data Act mean for businesses?
As US funding falters, mRNA cancer vaccine pioneers face new hurdles
Podcast: key trials and trends from ESC Congress 2025
Cell and gene therapies on correction course but not sinking
